Survival benefit of neoadjuvant hepatic arterial infusion chemotherapy followed by hepatectomy for hepatocellular carcinoma with portal vein tumor thrombus

被引:5
|
作者
Hu, Zili [1 ,2 ]
Yang, Zhenyun [1 ,2 ]
Wang, Jiongliang [1 ,2 ]
Fu, Yizhen [1 ,2 ]
Hu, Zhiwen [1 ,2 ]
Zhou, Zhongguo [1 ,2 ]
Chen, Minshan [1 ,2 ]
Zhang, Yaojun [1 ,2 ]
机构
[1] Sun Yat Sen Univ, Canc Ctr, Dept Liver Surg, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China
关键词
HCC; hepatocellular carcinoma; PVTT; portal vein tumor thrombus; HAIC; neoadjuvant hepatic arterial infusion chemotherapy; hepatoectomy; neoadjuvant therapy; C-REACTIVE PROTEIN; PHASE-II TRIAL; TRANSARTERIAL CHEMOEMBOLIZATION; CISPLATIN; LIVER; RADIOEMBOLIZATION; SORAFENIB; RESECTION; EFFICACY; SAFETY;
D O I
10.3389/fphar.2023.1223632
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background/purpose: The prognosis of hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT) is generally poor and hepatectomy is optional for these patients. This study aims to explore the survival benefits of neoadjuvant hepatic arterial infusion chemotherapy (HAIC) for resectable HCC with PVTT.Methods: This retrospective study included 120 resectable HCC patients with PVTT who underwent hepatectomy, from January 2017 to January 2021 at Sun Yat-sen University Cancer Center. Of these patients, the overall survival (OS) and recurrence-free survival (RFS) of 55 patients who received hepatectomy alone (Surgery group) and 65 patients who received neoadjuvant HAIC followed by hepatectomy (HAIC-Surgery group) were compared. Logistic regression analysis was conducted to develop a model predicting the response to neoadjuvant HAIC.Results: The OS rates for the HAIC-Surgery group at 1, 3, and 5 years were 94.9%, 78%, and 66.4%, respectively, compared with 84.6%, 47.6%, and 37.2% in the Surgery group (p < 0.001). The RFS rates were 88.7%, 56.2%, and 38.6% versus 84.9%, 38.3%, and 22.6% (p = 0.002). The subgroup analysis revealed that the survival benefit of neoadjuvant HAIC was limited to patients who responded to it. The logistic model, consisting of AFP and CRP, that predicted the response to neoadjuvant HAIC performed well, with an area under the ROC curve (AUC) of 0.756.Conclusion: Neoadjuvant HAIC followed by hepatectomy is associated with a longer survival outcome than hepatectomy alone for HCC patients with PVTT and the survival benefit is limited to patients who respond to neoadjuvant FOLFOX-HAIC.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Comparison Between Portal Vein Perfusion Chemotherapy and Neoadjuvant Hepatic Arterial Infusion Chemotherapy for Resectable Intermediate to Advanced Stage Hepatocellular Carcinoma
    Pan, Yangxun
    Mei, Jie
    Chen, Jinbin
    Zhang, Deyao
    Wang, Juncheng
    Wang, Xiaohui
    Yi, Minjiang
    Zhou, Zhongguo
    Zhang, Yaojun
    Chen, Minshan
    Guo, Rongping
    Xu, Li
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (03) : 2016 - 2029
  • [32] Comparison Between Portal Vein Perfusion Chemotherapy and Neoadjuvant Hepatic Arterial Infusion Chemotherapy for Resectable Intermediate to Advanced Stage Hepatocellular Carcinoma
    Yangxun Pan
    Jie Mei
    Jinbin Chen
    Deyao Zhang
    Juncheng Wang
    Xiaohui Wang
    Minjiang Yi
    Zhongguo Zhou
    Yaojun Zhang
    Minshan Chen
    Rongping Guo
    Li Xu
    Annals of Surgical Oncology, 2022, 29 : 2016 - 2029
  • [33] Survival benefit of TACE combined with sorafenib for hepatocellular carcinoma patients with portal vein tumor thrombus
    Luo, Bin
    Chen, Zhen-Hua
    Zhang, Xiu-Ping
    Wang, Meng
    Cheng, Shu-Qun
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S293 - S295
  • [34] Transarterial embolization and low-dose continuous hepatic arterial infusion chemotherapy with oxaliplatin and raltitrexed for hepatocellular carcinoma with major portal vein tumor thrombus
    Lin-Zhong Zhu
    Song Xu
    Hai-Long Qian
    World Journal of Gastroenterology, 2018, (23) : 2501 - 2507
  • [35] Transarterial embolization and low-dose continuous hepatic arterial infusion chemotherapy with oxaliplatin and raltitrexed for hepatocellular carcinoma with major portal vein tumor thrombus
    Zhu, Lin-Zhong
    Xu, Song
    Qian, Hai-Long
    WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (23) : 2501 - 2507
  • [36] Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radio Therapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombus
    Kodama, Kenichiro
    Aikata, Hiroshi
    Uchikawa, Shinsuke
    Kawaoka, Tomokazu
    Chayama, Kazuaki
    Tsuge, Masataka
    Nakahara, Takashi
    Imamura, Michio
    Hiramatsu, Akira
    Murakami, Eisuke
    HEPATOLOGY, 2018, 68 : 847A - 847A
  • [37] Hepatic arterial infusion chemotherapy versus sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombus: An updated meta-analysis and systematic review
    Zhang, Wei
    Ouyang, Deliang
    Huang, Zhangkan
    Che, Xu
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [38] A prognostic model to predict survival after hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein invasion.
    He, Jian
    Mo, Zhiqiang
    Mai, Qicong
    Shi, Feng
    Chen, Xiaoming
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus
    Minagawa, M
    Makuuchi, M
    Takayama, T
    Ohtomo, K
    ANNALS OF SURGERY, 2001, 233 (03) : 379 - 384
  • [40] Impact of Hepatectomy for Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombus
    Shohei Komatsu
    Masahiro Kido
    Kaori Kuramitsu
    Daisuke Tsugawa
    Hidetoshi Gon
    Kenji Fukushima
    Takeshi Urade
    Hiroaki Yanagimoto
    Hirochika Toyama
    Takumi Fukumoto
    Journal of Gastrointestinal Surgery, 2022, 26 : 822 - 830